Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017

Aptose Biosciences (NASDAQ:APTO) a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three months and year ended December 31, 2017 and reported on corporate developments. Unless specified otherwise, all amounts are in US Dollars.

As quoted in the press release:

The net loss for the quarter ended December 31, 2017 was $3.28 million ($0.12 per share) compared with $2.97 million ($0.23 per share) for the quarter ended December 31, 2016. Total cash and cash equivalents and investments as of December 31, 2017 were $11.4 million, or $13.3 million Canadian dollars, which, based on current operations and estimations, provide the Company with sufficient resources to fund research and development and operations into Q1 2019.

Click here to read the full press release.